Literature DB >> 19030166

Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo.

Philip Meuleman1, Joseph Hesselgesser, Matthew Paulson, Thomas Vanwolleghem, Isabelle Desombere, Hans Reiser, Geert Leroux-Roels.   

Abstract

UNLABELLED: The viral life cycle of the hepatitis C virus (HCV) has been studied mainly using different in vitro cell culture models. Studies using pseudoviral particles (HCVpp) and more recently cell culture-derived virus (HCVcc) suggest that at least three host cell molecules are important for HCV entry in vitro: the tetraspanin CD81, the scavenger receptor class B member I, and the tight junction protein Claudin-1. Whether these receptors are equally important for an in vivo infection remains to be demonstrated. We show that CD81 is indispensable for an authentic in vivo HCV infection. Prophylactic treatment with anti-CD81 antibodies completely protected human liver-uPA-SCID mice from a subsequent challenge with HCV consensus strains of different genotypes. Administration of anti-CD81 antibodies after viral challenge had no effect.
CONCLUSION: Our experiments provide evidence for the critical role of CD81 in a genuine HCV infection in vivo and open new perspectives for the prevention of allograft reinfection after orthotopic liver transplantation in chronically infected HCV patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19030166     DOI: 10.1002/hep.22547

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  95 in total

Review 1.  Animal models for studying hepatitis C and alcohol effects on liver.

Authors:  David F Mercer
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Study of hepatitis C virus entry in genetically humanized mice.

Authors:  Marcus Dorner; Charles M Rice; Alexander Ploss
Journal:  Methods       Date:  2012-06-08       Impact factor: 3.608

3.  A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

Authors:  Philip Meuleman; Maria Teresa Catanese; Lieven Verhoye; Isabelle Desombere; Ali Farhoudi; Christopher T Jones; Timothy Sheahan; Katarzyna Grzyb; Riccardo Cortese; Charles M Rice; Geert Leroux-Roels; Alfredo Nicosia
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

4.  Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display.

Authors:  Fang Chen; Yinglan Zhao; Min Liu; Dongqing Li; Hongyan Wu; Haidan Chen; Yongzhe Zhu; Fengling Luo; Jin Zhong; Yidan Zhou; Zhongtian Qi; Xiao-Lian Zhang
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

Review 5.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

6.  Gumming up the works: DNA polymers as HCV entry inhibitors.

Authors:  Natalie A Counihan; Brett D Lindenbach
Journal:  Gastroenterology       Date:  2009-06-27       Impact factor: 22.682

7.  Novel function of CD81 in controlling hepatitis C virus replication.

Authors:  Yong-Yuan Zhang; Bai-Hua Zhang; Koji Ishii; T Jake Liang
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

8.  Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes.

Authors:  Ana M Chamoun-Emanuelli; Eve-Isabelle Pecheur; Rudo L Simeon; Da Huang; Paul S Cremer; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

Review 9.  Towards a small animal model for hepatitis C.

Authors:  Alexander Ploss; Charles M Rice
Journal:  EMBO Rep       Date:  2009-10-16       Impact factor: 8.807

10.  Combined antiviral activity of interferon-alpha and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing.

Authors:  Qiuwei Pan; Scot D Henry; Herold J Metselaar; Bob Scholte; Jaap Kwekkeboom; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  J Mol Med (Berl)       Date:  2009-04-30       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.